Alexion's ambitions in rare diseases burning bright after takeover

22 April 2022

Rare diseases powerhouse Alexion was last year acquired for $39 billion by the Anglo-Swedish pharma major AstraZeneca (LSE: AZN), becoming part of one of big pharma’s most successful companies in recent years.

But this major milestone has not altered Alexion’s burning ambitions in rare diseases, and indeed it has bolstered the company’s drive to deliver more medicines to more patients around the world.

"We needed to increase our development capabilities"Evidence of this was provided last month with the announcement that Alexion is to establish a new global development hub in Barcelona, Spain, where up to 100 R&D specialists will be recruited over the next two years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK